A Glimpse Into The Expert Outlook On Exelixis Through 10 Analysts
Ratings for Exelixis (NASDAQ:EXEL) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 6 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 5 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $47.6, a high estimate of $54.00, and a low estimate of $35.00. Marking an increase of 4.85%, the current average surpasses the previous average price target of $45.40.
Interpreting Analyst Ratings: A Closer Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Exelixis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $54.00 | $52.00 |
| Leonid Timashev | RBC Capital | Raises | Sector Perform | $46.00 | $45.00 |
| Stephen Willey | Stifel | Raises | Hold | $44.00 | $43.00 |
| Eva Fortea Verdejo | Wells Fargo | Raises | Equal-Weight | $35.00 | $30.00 |
| Etzer Darout | Barclays | Raises | Equal-Weight | $44.00 | $41.00 |
| Robert Burns | HC Wainwright & Co. | Maintains | Buy | $52.00 | $52.00 |
| Sean Laaman | Morgan Stanley | Raises | Equal-Weight | $49.00 | $48.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $52.00 | $49.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $52.00 | $49.00 |
| Sean Laaman | Morgan Stanley | Raises | Equal-Weight | $48.00 | $45.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Exelixis. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Exelixis's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
To gain a panoramic view of Exelixis's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Exelixis analyst ratings.
All You Need to Know About Exelixis
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Exelixis's Economic Impact: An Analysis
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Exelixis showcased positive performance, achieving a revenue growth rate of 10.79% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exelixis's net margin is impressive, surpassing industry averages. With a net margin of 32.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Exelixis's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.23% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Exelixis's ROA excels beyond industry benchmarks, reaching 7.04%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.08.
What Are Analyst Ratings?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.